Tempus AI (TEM) Q3 2026 Earnings
GAAP net loss per share of $(0.08) included $50.8 million of stock-based compensation expense and related employer payroll taxes and $42.8 million in unrealized gains on marketable securities; non-GAAP figure excludes fair value changes of $(41,490) thousand, amortization of intangibles of $16,735 thousand and acquisition-related expenses of $3,728 thousand
How Did TEM Stock React to Q3 2026 Earnings?
Did TEM Beat Earnings? Q3 2026 Results
Yes. Tempus AI reported Q3 2026 earnings of $0.07 a share on Nov 2, 2026, beating the $-0.08 consensus estimate by 191.5%. Revenue was $411.5M against a $409.3M estimate.
Tempus AI delivered a decisive beat in the third quarter of 2026, posting adjusted earnings of $0.07 per share against a consensus estimate of negative $0.08, a 191.50% positive surprise that extended the company's streak of beating consensus EPS estimates to six consecutive quarters. Revenue of $411.54 million climbed 23.1% year over year and edged past the $409.30 million consensus by 0.55%, driven by strength across both reporting segments. Data and Applications revenue surged 33% to $108.07 million, with widening segment gross margin of 71.5%, while the larger Diagnostics segment contributed $303.47 million, up 20%, aided by a 300% volume increase in Minimal Residual Disease testing. Adjusted EBITDA of $25.57 million compared to just $1.48 million a year ago, underscoring the company's improving operating leverage. Recent data licensing momentum, including new multi-year collaborations with BMS, Merck, and Moderna, pushed year-to-date bookings above $550 million. Management raised full-year 2026 revenue guidance to approximately $1.60 billion, representing about 25% annual growth, while reiterating Adjusted EBITDA of roughly $65 million.
- Oncology volume growth accelerated to 32%
- MRD volume of ~12,000 tests, up 300%
- Data & Applications revenue up 33%, with Insights up 29%
- Hereditary revenue growth of only 3% offset Diagnostics growth
- Gross margin expanded to 64.8% from 62.8%, led by Data and Applications
- $42.8 million unrealized gains on marketable securities lifted GAAP results
- Lower interest expense of $6.7 million vs $15.4 million a year ago
“Q3 was another record quarter, as we delivered $411.5 million of revenue, led by accelerating unit growth of 32% in our oncology business and increasing momentum of 33% revenue growth in Data & Applications.”
Tempus AI CEO, on the earnings call
What Is Tempus AI's Outlook?
Tempus raised its full-year 2026 revenue guidance to $1.60 to $1.605 billion, representing about 25% annual growth. It continues to expect 2026 Adjusted EBITDA of about $65 million. The company does not provide guidance for GAAP net loss.
TEM YoY Financials
| Metric | Q3 2026 | Q3 2025 | Year over year |
|---|---|---|---|
| Revenue | $411.5M | $334.2M | +23.1% |
| Gross Profit | $266.7M | $205.9M | +29.5% |
| Operating Income | −$56.9M | −$54.1M | +5.1% |
| Net Income | −$14.9M | −$8.2M | +81.4% |
TEM Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.